Perguntar
Consultar
Descobrir
Calcular
Cadastre-se
Cadastre-se
Entrar
Entrar
Descobrir
FDA approval of enzalutamide (Xtandi) improves metastasis-free survival in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence - Notícias Vera Health